Nirmatrelvir/ritonavir also referred to as ritonavir-boosted nirmatrelvir, is an oral combination medication used to treat coronavirus disease 2019 (COVID-19). It consists of nirmatrelvir, a protease inhibitor targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease, and ritonavir, a cytochrome P450 (CYP) 3A inhibitor. Nirmatrelvir/ritonavir was authorized for emergency use on December 22, 2021. It is currently one of the highly-effective oral antiviral medications available to treat COVID-19. This activity reviews the medicationâ€™s indications and contraindications. It also reviews the mechanism of action, administration, monitoring, adverse effects, toxicity, and other elements related to treating patients with COVID-19. Information in this activity is pertinent to all members of the interprofessional healthcare team, including physicians, pharmacists, nurses, and other health professionals, who manage the care of patients with COVID-19.

**Objectives:**
- Outline the indications for using nirmatrelvir/ritonavir.
- Explain the potential adverse effects of nirmatrelvir/ritonavir.
- Describe the mechanism of action of nirmatrelvir/ritonavir.
- Summarize the contraindications of using nirmatrelvir/ritonavir to treat patients with COVID-19.